Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
GPCR
#1493
Structure Therapeutics Inc - American Depositary Shares
39.3
4
USD
-2.07%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
-2.07%
Monthly Change
-4.79%
6 month change
+11.57%
Year Change
+47.12%
Previous Close
40.1
7
Open
39.3
4
Low
39.3
4
High
39.3
4
Volume
48
Markets
US Stock Market
Healthcare
GPCR
Open full chart
Full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
2023
2024
2025
Total assets
482.02 M
903.33 M
1.58 B
Total liabilities
29.05 M
38.49 M
67.54 M
Total equity
452.97 M
864.84 M
1.52 B
Total liabilities & shareholders' equities
482.02 M
903.33 M
1.58 B
Total debt
—
—
—
Net debt
—
—
—
News
LLY Stock Gains 4% to All-Time High: Is Obesity Access the Catalyst?
Can EU Label Expansions of NVO's GLP-1 Drugs Spur Sales Growth?
LLY Reports Third Phase III Win for Next-Generation Obesity Drug
Can Mounjaro, Zepbound & Foundayo Keep Fueling LLY's Growth Story?
Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure?
Lilly Bets on Next-Generation Obesity Drugs to Stay Ahead
NVO Rallies 21% in a Month: How Should Investors Play the Stock?
LLY Stock Pops 16% After Beat-and-Raise Q1: Buy, Hold or Take Profits?
Lilly's Oral GLP-1 Pill Foundayo Starts Strong in Oral Obesity Market
Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?
Kailera Stock (KLRA) Rockets 68% after IPO in Race for $150B Obesity Market - TipRanks.com
LLY's Oral GLP-1 Pill Foundayo Shows Heart Benefits in Diabetes Study